159 related articles for article (PubMed ID: 34910380)
1. Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Lien RY; Tung HH; Wu SL; Hu SH; Lu LC; Lu SF
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1532. PubMed ID: 34910380
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
3. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
4. [Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
Chen X; Jiang Y; Zhang Y; Dai W; Fan R; Weng X; He P; Yan F; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1488-1492. PubMed ID: 33118519
[TBL] [Abstract][Full Text] [Related]
5. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Wang P; Tan G; Zhu M; Li W; Zhai B; Sun X
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):1-8. PubMed ID: 28847184
[TBL] [Abstract][Full Text] [Related]
6. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
7. Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?
Negri FV; Porta C
J Clin Oncol; 2015 Oct; 33(28):3219-20. PubMed ID: 26215963
[No Abstract] [Full Text] [Related]
8. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
9. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma.
Naganuma A; Hoshino T; Ohno N; Ogawa Y; Murakami T; Horiguchi S; Uehara D; Suzuki Y; Hatanaka T; Kudo T; Ishihara H; Sato K; Kakizaki S; Takagi H
In Vivo; 2019; 33(1):155-161. PubMed ID: 30587616
[TBL] [Abstract][Full Text] [Related]
10. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
14. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for sorafenib-induced hand-foot skin reaction using ordered logistic regression analysis.
Kanbayashi Y; Hosokawa T; Yasui K; Hongo F; Yamaguchi K; Moriguchi M; Miki T; Itoh Y
Am J Health Syst Pharm; 2016 Jan; 73(1):e18-23. PubMed ID: 26683674
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Keating GM; Santoro A
Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
[TBL] [Abstract][Full Text] [Related]
18. Painful Rashes on the Palms and Soles.
Bhullar M; Bhullar A; Arachchi NJ
Ann Acad Med Singap; 2016 Oct; 45(10):479-480. PubMed ID: 27832225
[No Abstract] [Full Text] [Related]
19. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
20. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Ochi M; Kamoshida T; Ohkawara A; Ohkawara H; Kakinoki N; Hirai S; Yanaka A
World J Gastroenterol; 2018 Jul; 24(28):3155-3162. PubMed ID: 30065561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
